Latest News On Obesity

Latest KFF Health News Stories

A Revolutionary Drug for Extreme Hunger Offers Clues to Obesity’s Complexity

KFF Health News Original

A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.

Trump Won’t Force Medicaid To Cover GLP-1s for Obesity. A Few States Are Doing It Anyway.

KFF Health News Original

Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.

Junk Food Turns Public Villain as Power Shifts in Washington

KFF Health News Original

Some Trump insiders are ready to take on the food industry. It remains to be seen whether their entrée will result in any meaningful change in government oversight of “Big Food” — or in American health.

How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices

KFF Health News Original

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”

Copycat Weight-Loss Drugs Are Major Players With Consumers

KFF Health News Original

As many as 1 in 8 American adults has tried one of the GLP-1 anti-obesity drugs, but a surprising number aren’t getting their supplies from pharma giants Novo Nordisk or Eli Lilly. Up to 30 percent of the market, by some estimates, is made up of copycat versions from compounding pharmacies. Compounding is legal, though […]

Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs

KFF Health News Original

Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.

Weight-Loss Drugs Are So Popular They’re Headed for Medicare Negotiations

KFF Health News Original

The steep prices — and popularity — of Ozempic and similar weight-loss and diabetes drugs could soon make them a priority for Medicare drug price negotiations. List prices for a month’s supply of the drugs range from $936 to $1,349, according to the Peterson-KFF Health System Tracker. The Inflation Reduction Act President Biden signed in […]

High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment

KFF Health News Original

The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.

Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo

KFF Health News Original

La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.

Arkansas Led the Nation in Measuring Obesity in Kids. Did It Help?

KFF Health News Original

For more than 20 years, children in Arkansas have been measured in school as part of a statewide effort to reduce childhood obesity. But the letters have had no impact on weight loss — and obesity rates have risen. Still, the practice of sending letters has spread to other states.

KFF Health News' 'What the Health?': On Abortion Rights, Ohio Is the New Kansas

Podcast

Nearly a year to the day after Kansas voters surprised the nation by defeating an anti-abortion ballot question, Ohio voters defeated a similar, if cagier, effort to limit access in that state. This week, they rejected an effort to raise the threshold for approval of future ballot measures from a simple majority, which would have made it harder to protect abortion access with yet another ballot question come November. Meanwhile, the number of Americans without health insurance has dropped to an all-time low, though few noticed. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Roubein of The Washington Post, and Emmarie Huetteman of KFF Health News join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Kate McEvoy, executive director of the National Association of Medicaid Directors, about how the “Medicaid unwinding” is going, as millions have their eligibility for coverage rechecked.

Seeking Medicare Coverage for Weight Loss Drugs, Pharma Giant Courts Black Influencers

KFF Health News Original

Novo Nordisk, the dominant company in the multibillion-dollar market for weight loss drugs, focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease that needs treatment.

Survey: Americans Want Weight Loss Drugs Despite High Cost

KFF Health News Original

A new poll reveals enthusiasm for a pricey new generation of weight loss drugs, but interest drops if users potentially have to deal with weekly injections, lack of insurance coverage, or a need to continue the medications indefinitely to avoid regaining weight.